July round-up of pharma/biotech M&A activity

2 August 2016
mergers-acquisitions-big

Given that summer was underway and the Brexit vote was being digested, July was a surprisingly busy month in pharma and biotech, with a number of noteworthy acquisitions.

Among the most interesting was the small $288,300 deal to help Tiziana Life Sciences (AIM:TILS) to study the secrets of the Sardinian population's health into old age, and the much bigger $1.3 billion acquisition of Gland Pharma by Fosun (HK: 02196), showing evidence of a Chinese company looking to gain a greater presence internationally.

Biggest deal:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical